Jose Espejo Valle-Inclán,Solange De Noon,Katherine Trevers,Hillary Elrick,Ianthe A. E. M. van Belzen,Sonia Zumalave,Carolin M. Sauer,M. Tanguy,Thomas Butters,Francesc Muyas,Alistair G. Rust,Fernanda Amary,Roberto Tirabosco,Adam Giess,Alona Sosinsky,Greg Elgar,Adrienne M. Flanagan,Isidro Cortés‐Ciriano
Osteosarcoma is the most common primary cancer of the bone, with a peak incidence in children and young adults. Using multi-region whole-genome sequencing, we find that chromothripsis is an ongoing mutational process, occurring subclonally in 74% of osteosarcomas. Chromothripsis generates highly unstable derivative chromosomes, the ongoing evolution of which drives the acquisition of oncogenic mutations, clonal diversification, and intra-tumor heterogeneity across diverse sarcomas and carcinomas. In addition, we characterize a new mechanism, termed loss-translocation-amplification (LTA) chromothripsis, which mediates punctuated evolution in about half of pediatric and adult high-grade osteosarcomas. LTA chromothripsis occurs when a single double-strand break triggers concomitant TP53 inactivation and oncogene amplification through breakage-fusion-bridge cycles. It is particularly prevalent in osteosarcoma and is not detected in other cancers driven by TP53 mutation. Finally, we identify the level of genome-wide loss of heterozygosity as a strong prognostic indicator for high-grade osteosarcoma.